1. 2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era. (20th October 2022) Authors: Inoa, Jennifer Olalla; Escudero, Laura Sanchez; Manzano, Aranzazu; Marquina, Gloria; Coronado, Pluvio; Garcia-santos, Francisco Javier; Bellon, Monica; Morillas, Leticia Sanchez; Rivas, Montserrat Fernandez; Fernandez, Ramiro Mendez; Segura, Pedro Perez; Casado, Antonio Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗